ESPOO, Finland, June 29, 2016 -- Technology, engineering and project management company Neste Jacobs has worked on an assignment to prepare conceptual and basic design for Asia's largest human blood plasma fractionation plant project.
These phases of the project are now successfully completed to enable the implementation of the project by Sichuan Yuanda Shuyang Pharmaceutical Company.
Neste Jacobs has accumulated vast experience in human plasma fractionation over the last 40 years and the company has in-depth understanding of plasma technologies, production processes, operational aspects and cost levels required for a fully functional human plasma fractionation plant. This highly regulated biopharmaceutical sector sets high standards for the design and operation of the facility. Product safety, regulatory compliance, traceability and robust operability must be built-in during all design steps starting from conceptual and basic design now completed by Neste Jacobs.
"This project demonstrates that we are the world's leading expert in this very demanding bioindustry field", says Neste Jacobs CEO, Jarmo Suominen. "We have thorough understanding of various blood plasma technologies and a comprehensive network of partnerships in this field taking us way beyond our competition."
The plant now goes to the implementation phase, being built in China. "During the conceptual and basic phases of this project we have greatly contributed to our customer quality and functionality of the plant.
Our approach integrates technology, concepts and process knowledge within the automated operations and constructability. This way our customers can be confident about the functionality of the as such complex plasma fractionation plant", says Neste Jacobs Bioindustries Sales Director, Kari Kaskes. "We are without doubt a number one company in front line development of global bioindustries."
Read more about Neste Jacobs' Biopharma expertise at http://www.nestejacobs.com/industries/biopharma/
For more information, please contact:
Jarmo Suominen, CEO, Neste Jacobs Oy, tel. +358 50 458 3399
Kari Kaskes, Sales Director, Bioindustries, Neste Jacobs Oy, tel. + 358 50 458 9603
Neste Jacobs is a preferred solution provider of high-quality technology, engineering and project services for a wide range of industries in the fields of oil and gas, petrochemicals, chemicals, biorefining, biochemicals, biopharma and industrial infrastructure. We have 60 years of experience in technology development and industrial investment projects as well as maintenance and performance improvement in Europe, North and South America, Asia and the Middle East. In addition to our home market Nordic countries we are looking to grow in the global expanding markets. We employ 1300 professionals globally. www.nestejacobs.com
HUG#2023616


Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
OpenAI Addresses Security Vulnerability in macOS App Certification Process
Bill Ackman Eyes New Fund to Bet Against Market Complacency
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 



